Physician profile
Robin Matheny
NPI 1962043547
$4,900.36
in general payments reported to CMS, 2019-2025
40 companies · $2,610 in 2025
The $2,610 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $765 · 2022: $357 · 2023: $188 · 2024: $980 · 2025: $2,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,440 · Education: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,440.21 |
| Education | $338.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $749.83 | 2021-2025 | Cresemba, Vyloy |
| Janssen Biotech, INC. | $447.80 | 2021-2025 | Tecvayli, Darzalex, Carvykti |
| Celgene Corporation | $354.33 | 2021-2025 | Breyanzi, Reblozyl |
| Adaptive Biotechnologies Corporation | $314.84 | 2022-2025 | Clonoseq |
| Sanofi-Aventis U.S. LLC | $234.14 | 2024-2025 | |
| Daiichi Sankyo INC. | $205.14 | 2024-2025 | Vanflyta, Injectafer |
| Incyte Corporation | $168.52 | 2024-2025 | Jakafi, Niktimvo, Monjuvi |
| Lilly USA, LLC | $150.94 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Kadmon Pharmaceuticals LLC | $140.65 | 2021 | |
| Merck Sharp & Dohme LLC | $137.78 | 2024-2025 | Prevymis, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $136.47 | 2021-2025 | |
| Abbvie INC. | $132.83 | 2024-2025 | |
| Genentech, INC. | $128.06 | 2025 | Polivy |
| Jazz Pharmaceuticals INC. | $124.56 | 2024 | |
| Sobi, INC | $122.58 | 2024-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $114.29 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.96 | 2024-2025 | Ninlaro, Livtencity, Iclusig |
| Biolinerx USA, INC. | $105.36 | 2024 | Aphexda |
| Seagen INC. | $99.00 | 2025 | |
| Kyowa Kirin, INC. | $91.19 | 2024-2025 | Poteligeo |
| Genzyme Corporation | $77.12 | 2025 | |
| Beone Medicines USA, INC. | $69.79 | 2025 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $66.49 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Blueprint Medicines Corporation | $58.27 | 2024-2025 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $55.42 | 2025 | |
| Genentech USA, INC. | $50.28 | 2024-2025 | Columvi, Lunsumio, Venclexta |
| Karyopharm Therapeutics INC. | $49.58 | 2025 | Xpovio |
| Servier Pharmaceuticals LLC | $46.31 | 2025 | |
| Genmab U.S., INC. | $46.07 | 2024-2025 | Epkinly |
| Glaxosmithkline, LLC. | $42.29 | 2025 | Blenrep, Ojjaara |
| Invivyd INC | $41.40 | 2024 | Pemgarda |
| Syndax Pharmaceuticals, INC. | $36.63 | 2025 | |
| Taiho Oncology, INC. | $30.21 | 2024 | |
| Legend Biotech USA INC. | $29.20 | 2025 | Carvykti |
| E.R. Squibb & Sons, L.L.C. | $28.96 | 2025 | Breyanzi |
| Beigene USA, INC. | $24.67 | 2024 | Brukinsa |
| Tersera Therapeutics LLC | $21.64 | 2025 | Quzyttir |
| Ipsen Biopharmaceuticals, INC | $19.69 | 2025 | Onivyde |
| Geron Corporation | $18.56 | 2025 | Rytelo |
| Pfizer INC. | $17.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Matheny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.